QC
ORMP icon

Quadrature Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Quadrature Capital’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,734
Closed -$119K – 1726
2025
Q4 		$119K Buy
+41,734
New +$108K ﹤0.01% 1072

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Quadrature Capital's ORMP Position: Q1 2026 in Review

Quadrature Capital sold out of Oramed Pharmaceuticals (ORMP) in Q1 2026, closing a stake of 41,734 shares — an estimated $119K sold.

Quadrature Capital first reported a position in ORMP in Q4 2025 and held it in 1 quarter. The position peaked at $119K in Q4 2025. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Quadrature Capital reported no remaining Oramed Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 41,734 Oramed Pharmaceuticals shares in Q1 2026, an estimated $119K.
  • Quadrature Capital first reported a position in Oramed Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Quadrature Capital's Oramed Pharmaceuticals position peaked at $119K in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.